402 reports of this reaction
2.9% of all EMTRICITABINE reports
#5 most reported adverse reaction
VIROLOGIC FAILURE is the #5 most commonly reported adverse reaction for EMTRICITABINE, manufactured by Gilead Sciences, Inc.. There are 402 FDA adverse event reports linking EMTRICITABINE to VIROLOGIC FAILURE. This represents approximately 2.9% of all 13,674 adverse event reports for this drug.
Patients taking EMTRICITABINE who experience virologic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIROLOGIC FAILURE is a less commonly reported adverse event for EMTRICITABINE, but still significant enough to appear in the safety profile.
In addition to virologic failure, the following adverse reactions have been reported for EMTRICITABINE:
The following drugs have also been linked to virologic failure in FDA adverse event reports:
VIROLOGIC FAILURE has been reported as an adverse event in 402 FDA reports for EMTRICITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIROLOGIC FAILURE accounts for approximately 2.9% of all adverse event reports for EMTRICITABINE, making it a notable side effect.
If you experience virologic failure while taking EMTRICITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.